CohBar (CWBR) is a company working to combat the diseases of aging that has tremendous upside potential. This is because the markets they are targeting-NASH, obesity, type 2 diabetes, fibrotic diseases, and cancer-are all huge, yet the company's market cap is under $150 million. CohBar is seeking to treat these diseases of aging and generally have an impact of human longevity by utilizing cutting-edge mitochondrial-based medicine. CohBar management has done a good job getting pipeline assets into the clinic without spending huge amounts of cash so far, a great sign for any early